Sriskandan S, McKee A, Hall L, Cohen J
Department of Infectious Diseases, Royal Postgraduate Medical School, London, UK.
J Antimicrob Chemother. 1997 Aug;40(2):275-7. doi: 10.1093/jac/40.2.275.
We have tested the ability of Streptococcus pyogenes to produce streptococcal pyrogenic exotoxin A (SPEA) and superantigenic activity in the presence of sub-inhibitory concentrations of ampicillin and clindamycin. After 6 h of culture, SPEA production by S. pyogenes was higher in broths containing ampicillin (715.7 +/- 296.4 pg/10(6) cfu) than in broths containing clindamycin (167.1 +/- 31.9 pg/10(6) cfu), a difference that was not significant (P = 0.25). Promitogenic activity of bacterial supernatants was also greater in ampicillin-treated cultures (467.5 +/- 17.2 ccpm/10(6) cfu) than in clindamycin-treated cultures (169.2 +/- 8.9 ccpm/10(6) cfu), a difference that was highly significant (P = 0.0001). The data support the use of clindamycin in the treatment of streptococcal toxic shock-like syndrome, in order to inhibit superantigen synthesis.
我们检测了化脓性链球菌在亚抑菌浓度的氨苄西林和克林霉素存在下产生化脓性链球菌致热外毒素A(SPEA)的能力以及超抗原活性。培养6小时后,化脓性链球菌在含氨苄西林的肉汤中产生的SPEA(715.7±296.4 pg/10⁶ cfu)高于含克林霉素的肉汤(167.1±31.9 pg/10⁶ cfu),但差异不显著(P = 0.25)。氨苄西林处理的培养物中细菌上清液的促有丝分裂活性(467.5±17.2 ccpm/10⁶ cfu)也高于克林霉素处理的培养物(169.2±8.9 ccpm/10⁶ cfu),差异极显著(P = 0.0001)。这些数据支持使用克林霉素治疗链球菌中毒性休克样综合征,以抑制超抗原合成。